CME Group (CME) Piper Sandler Global Exchange and Trading Conference 2024 summary
Event summary combining transcript, slides, and related documents.
Piper Sandler Global Exchange and Trading Conference 2024 summary
1 Feb, 2026Market environment and outlook
Open interest is up 15% year to date, with continued rate uncertainty and a highly active market expected due to global and U.S. elections in the second half of the year.
Market participants have been caught off guard by Fed policy, leading to volatility and active trading.
The U.S. presidential election and speculation about candidates add uncertainty for business and regulation.
Energy markets have been unusually stable, with oil prices stuck in a narrow range despite geopolitical tensions, attributed to U.S. capacity and political expectations.
Competitive landscape and strategy
Confident in defending the interest rate complex, citing record treasury contract volumes and significant margin savings for large banks.
Criticized competitors for making claims without proven contracts and highlighted misinformation about margin advantages.
Emphasized the importance of liquidity, customer service, and operational reliability as key differentiators.
Will remain aggressive in protecting market share and believes existing efficiencies provide a strong moat.
Growth opportunities and product innovation
Launched corporate bond trading on BrokerTec and U.S. credit futures, viewing timing as critical for success in U.S. credit markets.
Applied to clear U.S. Treasuries, aiming to be prepared for regulatory changes in 2026, with minimal risk to investors.
Sees the equity markets as a major growth driver, expecting broader participation and increased hedging activity, especially from international institutions.
Open to expanding product offerings and efficiencies, potentially through M&A or new product development.
Latest events from CME Group
- Shareholders will vote on director elections, auditor ratification, and key governance amendments.CME
Proxy filing23 Mar 2026 - Shareholders to vote on major governance reforms, executive pay, and director elections.CME
Proxy filing23 Mar 2026 - Proposal to eliminate Class B director election rights, with payments to affected shareholders.CME
Proxy Filing12 Mar 2026 - Shareholders to vote on eliminating Class B director election rights amid record financial performance.CME
Proxy Filing12 Mar 2026 - Global growth, product innovation, and high margins drive record performance and shareholder returns.CME
47th Annual Raymond James Institutional Investor Conference3 Mar 2026 - Record 2025 growth fueled by innovation, global reach, and strong capital efficiencies.CME
Investor presentation3 Mar 2026 - Record revenue, earnings, and trading volumes in 2025, with strong capital returns.CME
Q4 20254 Feb 2026 - Record financials, all proposals approved, and strong outlook amid competition and litigation.CME
AGM 20253 Feb 2026 - Record Q2 revenue, net income, and trading volumes, with growth in every asset class and strong margins.CME
Q2 20243 Feb 2026